Literature DB >> 23504258

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.

Hairui Sun1, Lianhu Yin, Showwei Li, Song Han, Guangrong Song, Ning Liu, Changxiang Yan.   

Abstract

Mutations in the gene encoding isocitrate dehydrogenase (IDH) have been identified in approximately 65-90 % of low-grade gliomas (LGGs). Various studies examining the relationship between IDH mutation with the clinical outcome in patients with LGGs have yielded inconclusive results. The purpose of the present meta-analysis of literature is to determine this effect. We conducted a meta-analysis of 10 studies (937 patients) that evaluated the correlation between IDH mutation and overall survival (OS). For the quantitative aggregation of the survival results, the IDH mutation effect was measured by hazard ratio (HR). Overall, the pooled HR was 0.585 (95 % CI, 0.376-0.911, p = 0.025, random effect model) for patients with IDH mutation vs patients without IDH mutation. IDH mutation was associated with better overall survival of LGGs. At least this trend was observed in our analysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504258     DOI: 10.1007/s11060-013-1107-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  46 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.

Authors:  Angelica A Saetta; Georgia Levidou; Elias A El-Habr; Ioannis Panayotidis; Vassilis Samaras; Irene Thymara; Stratigoula Sakellariou; Efstathios Boviatsis; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

3.  Molecular signatures classify astrocytic gliomas by IDH1 mutation status.

Authors:  Grischa Toedt; Sebastian Barbus; Marietta Wolter; Jörg Felsberg; Björn Tews; Frederic Blond; Michael C Sabel; Stefanie Hofmann; Natalia Becker; Christian Hartmann; Hiroko Ohgaki; Andreas von Deimling; Otmar D Wiestler; Meinhard Hahn; Peter Lichter; Guido Reifenberger; Bernhard Radlwimmer
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

4.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

5.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

6.  Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.

Authors:  Shasha Lv; Erik Teugels; Jan Sadones; Erik Quartier; Mike Huylebrouck; Stephanie DU Four; Marie LE Mercier; Olivier DE Witte; Isabelle Salmon; Alex Michotte; Jacques DE Grève; Bart Neyns
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

7.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

8.  Molecular classification of low-grade diffuse gliomas.

Authors:  Young-Ho Kim; Sumihito Nobusawa; Michel Mittelbronn; Werner Paulus; Benjamin Brokinkel; Kathy Keyvani; Ulrich Sure; Karsten Wrede; Yoichi Nakazato; Yuko Tanaka; Anne Vital; Luigi Mariani; Robert Stawski; Takuya Watanabe; Umberto De Girolami; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2010-11-12       Impact factor: 5.770

9.  IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 13.801

10.  IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Authors:  Marta Mellai; Angela Piazzi; Valentina Caldera; Oriana Monzeglio; Paola Cassoni; Guido Valente; Davide Schiffer
Journal:  J Neurooncol       Date:  2011-06-04       Impact factor: 4.506

View more
  18 in total

Review 1.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

2.  Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Authors:  Catherine Gozé; Marie Blonski; Guillaume Le Maistre; Luc Bauchet; Edouard Dezamis; Philippe Page; Pascale Varlet; Laurent Capelle; Bertrand Devaux; Luc Taillandier; Hugues Duffau; Johan Pallud
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

Review 3.  New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.

Authors:  Michael Karsy; Jian Guan; Adam L Cohen; Randy L Jensen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

4.  Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.

Authors:  Xiaogang Wang; Xiaoming Li; Feng Xu; Youqian Zhang; Hongwei Liu; Yingqun Tao
Journal:  Mol Neurobiol       Date:  2015-09-08       Impact factor: 5.590

5.  Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis.

Authors:  Xiao-Yan He; Yu-Dong Liao; Xiao-Qing Guo; Robin Wang; Zhen-Yu Xiao; Yan-Gang Wang
Journal:  Mol Neurobiol       Date:  2015-03-20       Impact factor: 5.590

Review 6.  The Effect of Molecular Diagnostics on the Treatment of Glioma.

Authors:  Nancy Ann Oberheim Bush; Nicholas Butowski
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

7.  T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings.

Authors:  Shinji Yamashita; Hideo Takeshima; Yoshihito Kadota; Minako Azuma; Tsuyoshi Fukushima; Natsuki Ogasawara; Tomoki Kawano; Mitsuru Tamura; Jyunichiro Muta; Kiyotaka Saito; Go Takeishi; Asako Mizuguchi; Takashi Watanabe; Hajime Ohta; Kiyotaka Yokogami
Journal:  Brain Tumor Pathol       Date:  2022-04-28       Impact factor: 3.298

Review 8.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

9.  Radiotherapy in adult low-grade glioma: nationwide trends in treatment and outcomes.

Authors:  R S Nunna; S Khalid; J S Ryoo; A Sethi; R W Byrne; A I Mehta
Journal:  Clin Transl Oncol       Date:  2020-07-20       Impact factor: 3.405

Review 10.  2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.

Authors:  Daniel R Wahl; Sriram Venneti
Journal:  Brain Pathol       Date:  2015-11       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.